Showing 5401-5410 of 5792 results for "".
- LEO Launches Taclonex in Larger Package Sizehttps://practicaldermatology.com/news/20130730-leo_launches_taclonex_in_larger_package_size/2459488/LEO Pharma Inc., has launched a patient-friendly 120g package size of Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of plaque psoriasis.
- iovera Treatment Approved in Canadahttps://practicaldermatology.com/news/20130725-iovera_treatment_approved_in_canada/2459492/ioveradegrees received regulatory approval in Canada. Developed by myoscience, inc. in California, the ioveradegrees system targets forehead wrinkles using Focused Cold TherapyTM, a technology that helps to temporarily reduce the appearance of wrinkles without leaving any toxins or chemicals behind
- Mentor, Medicis Unveiling Joint New Physician Loyalty Programhttps://practicaldermatology.com/news/20130717-mentor_medicis_unveiling_joint_new_physician_loyalty_program/2459494/Mentor Worldwide, LLC and Valeant's Medicis division have entered into a Collaboration Agreement to form a joint physician loyalty program called the M2VP P
- Galen Acquires Local Dermal Analgesia Drug Synerahttps://practicaldermatology.com/news/20130716-galen_acquires_local_dermal_analgesia_drug_synera/2459495/Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma, Inc., a wholly owned subsidiary of Nuvo Research Inc. Synera® is indicated for use on intact skin t
- "What Not to Wear" Co-Host Partners with AbbVie on Psoriasis Campaignhttps://practicaldermatology.com/news/20130716-what_not_to_war_co-host_partners_with_abbvie_on_psoriasis_campaign/2459496/Stacy London, of TLC's "What Not to Wear," is partnering with AbbVie on a new psoriasis campaign called <a href="http://www.uncoveryourconfidence.com/">Uncover Your Confidence</a>. The campaign features educational resources and style advice for millions of Americans living with psoriasi
- Investigational Psoriasis Agent On Track for Regulatory Submission This Yearhttps://practicaldermatology.com/news/20130708-investigational_psoriasis_agent_on_track_for_regulatory_submission_this_year/2459501/Results from a Phase III trial showed that the experimental drug secukinumab (Novartis) showed superiority to etanercept (Enbrel, Amgen) at clearing skin in patients with moderate-to-severe plaque psoriasis. The FIXTURE trial, which randomized 1,307 patients with moderate-to-severe plaque psoriasis,
- Merz North America Appoints New Vice Presidenthttps://practicaldermatology.com/news/20130702-merz_north_america_appoints_new_vice_president/2459503/Greg Besase has been appointed Vice President of Merz North America. Besase joined Merz in December 2012 as Director of Marketing, Dermatology and has served as the interim head of the U.S. Dermatology Business Unit since February 2013.
- ExtendCredit Launches “Cosmetic Credit Plans”https://practicaldermatology.com/news/20130702-extendcredit_launches_cosmetic_credit_plans/2459505/“Cosmetic Credit Plans” is a fully automated, customizable in-house financing software solution created specifically for the cosmetic surgery industry, offered by ExtendCredit. The software enables cosmetic surgeons to offer their own financi
- Naftin Gel 2% Approved for Interdigital-Type Tinea Pedishttps://practicaldermatology.com/news/20130702-naftin_gel_2_approved_for_interdigital-type_tinea_pedis/2459507/The FDA approved Naftin (naftifine HCl) Gel 2% for the treatment of interdigital-type tinea pedis from Merz North America. Naftin Gel 2% improves on the current formulation of Naftin Gel 1% by delivering the efficacy of naftifine hydochloride with
- MiraConnect Lets Candidates Interact with miraDry Treatment Veteranshttps://practicaldermatology.com/news/20130625-miraconnect_lets_candidates_interact_with_miradry_treatment_veterans/2459509/Offering an opportunity for interested to learn more about microwave-based therapy for hyperhidrosis, the miraConnect program from Miramar Labs enables treatment candidates to speak one-on-one with patients who have undergone the procedu